Imperial College Innovations Ltd.
For Sir Richard Sykes, chairman of GlaxoSmithKline PLC and Rector of Imperial College of Science Technology & Medicine since the beginning of 2001, strong interaction between different faculties is the key to effectively exploiting the College's intellectual assets. The interdisciplinary approach taken by the College itself-its new BioMedical building built in the heart of the campus, close to Chemistry and Engineering-and by Imperial College Innovations Ltd., the College's technology transfer company, reflects this belief. "The Rector's view is that the big technologies of the future will be founded at the interstices of the various faculties," outlines Jon Taylor, former CEO of Imperial College Innovations.
More from Archive
Optimizing Drug Pipelines With Biophysical Methods”, your view into how using biophysical techniques can enhance and streamline processes throughout the drug discovery and validation cycle.
- • By
CEO Paul Stoffels said gaining US clearance for an IND for its novel CAR-T product was demanding, but now opens up a pathway towards a pivotal study starting in 2025.
- • By
A final rejection of Leqembi could also spell the same fate for Lilly’s rival drug but public outcry and demand for Alzheimer’s therapies might force the regulator’s hand
- • By
GSK will assume full control of mRNA shots in infectious disease, allowing CureVac to cut costs and pivot its research to oncology.
More from Scrip
- Sponsored by :
As clinical trials grow more complex, execution pressures are changing where and how evidence is collected.
Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.






